ABSTRACT The aim of this study was to evaluate risk factors for occurrence of neonatal passive im mune thrombocytopenia (PIT) in pregnancy compli cated by idiopathic thrombocytopenic purpura (ITP). We studied 63 pregnant women with ITP and the 66 neonates retrospectively. Neonatal platelet counts were compared with maternal platelet counts, platelet-associated gamma G immunoglobulin (PAIgG) values, and the presence of antiplatelet antibody in the maternal circulation, history of previous PIT, maternal treatments for ITP, and other maternal or neonatal factors. PIT (platelet counts <100 X 10 3 /μL) was observed in 9 (14.3%) of 63 pregnancies. Presence of circulating antiplatelet antibody in ma ternal blood, splenectomy prior to pregnancy, and history of previous PIT were observed more fre quently with statistical significance in patients giving birth to neonates who developed PIT. No effect on oc currence of PIT was found by the administration of corticosteroids or immunoglobulin. Splenectomy prior to pregnancy was found by logistic regression analysis to be a single significant variable (p = 0.021, odds ratio 7.20, confidence intervals: 1.35 to 38.3) among the risk factors for PIT.
neonatal ICH has been identified at a very low incidence of 0 to 2.3%, [2] [3] [4] and many investigators have favored vaginal delivery unless cesarean section is obstetrically indicated. 1, 5, 6 There is considerable controversy regarding the issue of whether or not it is possible to predict which neonate will be thrombocytopenic. Direct measurement of fetal platelet count is not widely used, because fetal blood sampling by cordocentesis has small but significant risks of morbidity and mortality, 7 especially in the thrombocytopenic fetus. [8] [9] [10] Fetal scalp sampling also is technically difficult, 11 and an inaccurate platelet count can often be obtained by contaminations with maternal blood and sample clotting. 12 In previous studies, 1314 we have demonstrated that the presence of circulating antiplatelet antibodies, splenectomy prior to pregnancy, and history of previous PIT are risk factors for the occurrence of PIT. The current study was designed to investigate the predictive value of a variety of maternal and neonatal factors for the occurrence of PIT by assessing a larger number of pregnant women with ITP.
MATERIAL AND METHODS
Sixty-three consecutive ITP patients and their 66 neonates, including three sets of twins, who were born from January 1983 to October 1998 in Hokkaido University Hospital were enrolled in this retrospective study. The diagnosis of ITP was made on the basis of thrombocytopenia (platelet count < 100 × 10 3 /ΜL), the presence of normal or increased numbers of megakary ocytes in the bone marrow without splenomegaly or leukopenia, and laboratory findings such as a positive test for circulating antiplatelet antibodies and PAIgG. Neonatal PIT was diagnosed when a platelet count of the peripheral blood at birth was less than 100 × 10 3 /ΜL. If the platelet count at birth was less than 50 × 10 3 /ΜL, se vere PIT was diagnosed. Circulating antiplatelet anti bodies were detected by the method of platelet suspen sion immunofluorescence test (PSIFT). 15 
RESULTS
Maternal and neonatal characteristics of the sub jects are shown in Table 1 . Of the 66 neonates, 9 (13.6%) developed PIT and 5 had severe thrombocytopenia. No ICH was found in any neonate by either ultrasound or neurological examinations. Four neonates with severe PIT required administration of high-dose immunoglobu lin or corticosteroids, or both, and the high-dose immu noglobulin was effective in only 1 (case 2) of the 4 cases ( Table 2) .
By regression analysis, no relationship was found between neonatal platelet counts and maternal platelet counts (p = 0.200) ( (Fig. 2) . Of 49 women who were examined by PSIFT, 9 tested positive for circulating antiplatelet anti bodies at least once during pregnancy. The prevalence of PIT in women with a positive test was significantly higher than it was in women with negative tests (p <0.05) ( Table 3 ). The sensitivity of PSIFT for detection of PIT was 44.4%, and the specificity was 90.0%. The positive predictive value was 50.0%, and the negative predictive value was 87.5%. The six treatment groups for maternal ITP and their corresponding prevalence of PIT are shown in Table 4 .
The prevalence of PIT was significantly higher in pa tients with splenectomy prior to pregnancy (4/8) than it was in patients without splenectomy (5/55) (p <0.05).
In 30 multipara women we compared the preva lence of PIT between patients with (n = 6) and without a history of PIT (n = 24). Patients with a history of PIT had repeated PIT, with higher prevalence than in patients without the history (66.7% versus 4.2%, p <0.01).
In order to assess the value of each risk factor for PIT we performed logistic regression analysis for vari ables, including maternal platelet counts, presence of an tiplatelet antibodies, administration of corticosteroids, high-dose immunoglobulin and splenectomy prior to 
FIG. 2. Correlation between maternal PAIgG and neonatal platelet counts.
pregnancy, and other maternal and neonatal factors, including gestational age and birth weight. A history of previous PIT or PAIgG was not included as a variable; otherwise, 33 or 25 cases would be lost in the analysis. As a result, splenectomy prior to pregnancy was found as the only significant variable (p = 0.021), with an odds ratio of 7.20 (confidence intervals, 1.35 to 38.3). The other maternal and neonatal factors, including maternal platelet counts, gestational age, birth weight, presence of antiplatelet antibodies, administration of corticosteroids, or high-dose immunoglobulin, were found not to be a significant variable.
DISCUSSION
We found no correlation between maternal and neonatal platelet counts. Our data were also in good agreement with previous authors in finding no correla- 21 We also observed a higher prevalence of PIT in patients who tested positive at least once for circulating antiplatelet antibodies than we did in patients who consistently tested negative by PSIFT. The detection of circulating antiplatelet antibodies in maternal serum might indicate a risk of occurrence of PIT. However, as found in this study, both the specificity and the sensitivity of PIT prediction by PSIFT were relatively low. Recent studies showed that circulating antiplatelet antibodies directed against platelet membrane glycoprotein Ilb/IIIa, Ib/IX, and Ia/IIa might be more useful to distinguish ITP from gestational thrombocytopenia 2223 and might be helpful in detecting the increased risk for PIT. 24 In multipara patients, we found that patients with a history of PIT had a higher prevalence (66.7%) of recurrence than patients without the history had (4.2%). Other investigations on siblings from mothers with ITP revealed the concordant conclusion, showing a significant positive correlation of platelet counts between the siblings. 25 ' 26 Thus, the platelet count of the first baby may be useful for the management of the next pregnancy complicated by ITP.
High-dose intravenous immunoglobulin therapy in a pregnant woman with ITP was effectively performed for the first time in 1983. 27 We treated 24 patients with a total of 100 to 222.5 g of intravenous immunoglobulin. Excluding 1 patient who concomitantly received platelet infusions, 10 of 23 patients (43.5%) responded to the therapy with an increase of more than 50 × 10 3 /μL in their platelet counts. Maternal administration of corti costeroids 1, 28, 29 and intravenous immunoglobulin 30 ' 31 were once thought to decrease the prevalence of PIT. In a recent randomized prospective trial on antenatal treat ments with low-dose corticosteroids, however, neonatal thrombocytopenia was not prevented. 28 Corticosteroids may even promote transplacental passage of antiplatelet antibodies. 32 The influence of high-dose immunoglobu lin therapy on fetal PIT has been assumed to be the fol lowing: (1) a transplacental effect that increases the con centration of IgG and platelet counts in fetal blood through active transport of IgG and (2) an immunosup pressive effect that reduces production of antiplatelet an tibodies. However, our previous and other studies have reported no significant increase of fetal IgG concentra tion after maternal infusion of more than 100 g of immu noglobulin 1333 and unchanged amounts of maternal PAIgG before and after the infusion. 13 Others also have shown no benefit in increasing fetal platelet counts. 3435 Our current results failed to find any relation be tween corticosteroids or intravenous immunoglobulin treatment and occurrence of PIT. In this study, 5 (18.5%) of 27 patients who received preclonisolone and 4 (16.7%) of 24 patients who received high-dose immuno globulin had PIT. The prevalence of PIT in the group of preclonisolone alone and in the group of immunoglobu lin alone were 15.4 and 10.0%, respectively. Neither group was significantly different from the group with no medication or from the overall prevalence (14.3%). Thus, no effect on occurrence of PIT was found by the administration of corticosteroids or immunoglobulin.
In this study, four neonates with severe PIT re quired administration of high-dose immunoglobulin, but the high-dose immunoglobulin was effective in only one case. Two of the other three cases subsequently received corticosteroids and responded well to the treatment. Similarly, it was found that high-dose immunoglobulin was less effective than corticosteroids were in PIT, 36 al though some studies reported efficacy of immunoglobu lin in the neonatal period.
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Splenectomy prior to pregnancy was found to be the single significant factor for PIT among various ma ternal and neonatal factors by logistic regression analy sis, which was also found by other authors.
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Splenectomy possibly increases free antiplatelet anti bodies in the maternal sera, which can pass the placenta because of the removal of the immune complex destruc tion site. Titers of transferable antiplatelet antibodies might have increased in our patients with splenectomy prior to pregnancy. An alternative explanation for the in creased risk of PIT in patients with splenectomy is that the severity of ITP, a corticosteroid-resistant condition that required splenectomy treatment, is itself associated with the increase in high prevalence of PIT. In a mild status of ITP at sustained remission, the risk for the PIT might be very low. Actually, a very low prevalence of PIT in a no medication group (4.8%) was observed in this study. This was also found by other authors. 1, 21, 28, 32 The disease activity itself might be associated with higher risk of PIT.
In order to further understand the mechanism of PIT, a highly sensitive method for measurement of spe cific antiplatelet antibodies should be developed.
